Leukemia
Leukemia
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
34
Clinical Trials
Leukemia
Phase I
Accepting Patients
nct/study# NCT04310592 / CYNK-001-AML-001
A Phase I Multi-Dose Study Of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) In Adults With Actively Diagnosed Primary Or Secondary Acute Myeloid Leukemia (AML) In Morphologic Complete Remission With Minimal Residual Disease (MRD)
Learn More
Leukemia
Phase III
Accepting Patients
nct/study# NCT03165734 / PAC203
A Randomized, Controlled Phase 3 Study Of Pacritinib Versus Physician’s Choice In Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/Ìl)(PACIFICA)
Learn More
Leukemia
Phase III
Accepting Patients
nct/study# NA / COMPASSIONATE-USE-PACRITINIB
Individual Patient Supply Of Oral Pacritinib In A Patient With Thrombocytopenia And Primary Myelofibrosis.
Learn More
Leukemia
NA
Active
Leukemia
Phase I
Active
nct/study# NA / SY-2101-101
An Open-label Phase 1 Study to Evaluate Pharmacokinetics, Safety, and Tolerability of SY-2101 in Adult Patients with Acute Promyelocytic Leukemia
Learn More
Leukemia
Phase I/II
Active
nct/study# NA / TL-895-203
An Open-Label, Multicenter, Phase 1b/2 Study Of The Safety And Efficacy Of TL-895 Combined With KRT-232 In Subjects With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.